Abstract
Cancer is a disease promoted by excess angiogenesis. Interference with this process poses an attractive approach to controlling aberrant tumor growth, a hypothesis first proposed in the early 1970s that led to world-wide focus on identifying and developing angiogenesis inhibitors, which currently number in the hundreds. This review surveys the discovery and development of anti-angiogenic protein fragments and peptides, with a slant towards understanding their structure-function relationships to aid in the design of better therapeutic agents.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Angiogenesis Inhibitors / chemistry
-
Angiogenesis Inhibitors / metabolism*
-
Angiogenesis Inhibitors / therapeutic use
-
Animals
-
Drug Design
-
Endothelial Cells / metabolism
-
Humans
-
Neovascularization, Pathologic / drug therapy
-
Neovascularization, Pathologic / metabolism*
-
Peptide Fragments / chemistry
-
Peptide Fragments / metabolism*
-
Peptide Fragments / therapeutic use
-
Peptides / chemistry
-
Peptides / metabolism*
-
Peptides / therapeutic use
-
Structure-Activity Relationship
Substances
-
Angiogenesis Inhibitors
-
Peptide Fragments
-
Peptides